CA3168009A1 - Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors - Google Patents
Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitorsInfo
- Publication number
- CA3168009A1 CA3168009A1 CA3168009A CA3168009A CA3168009A1 CA 3168009 A1 CA3168009 A1 CA 3168009A1 CA 3168009 A CA3168009 A CA 3168009A CA 3168009 A CA3168009 A CA 3168009A CA 3168009 A1 CA3168009 A1 CA 3168009A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- inhibitor
- usp1
- parp
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062976864P | 2020-02-14 | 2020-02-14 | |
| US62/976,864 | 2020-02-14 | ||
| US202063032245P | 2020-05-29 | 2020-05-29 | |
| US63/032,245 | 2020-05-29 | ||
| US202163146937P | 2021-02-08 | 2021-02-08 | |
| US63/146,937 | 2021-02-08 | ||
| PCT/US2021/017912 WO2021163530A1 (en) | 2020-02-14 | 2021-02-12 | Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3168009A1 true CA3168009A1 (en) | 2021-08-19 |
Family
ID=77291879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3168009A Pending CA3168009A1 (en) | 2020-02-14 | 2021-02-12 | Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230277533A1 (https=) |
| EP (1) | EP4103165A4 (https=) |
| JP (1) | JP2023514568A (https=) |
| KR (1) | KR20220140732A (https=) |
| CN (1) | CN115066235A (https=) |
| AU (1) | AU2021218805A1 (https=) |
| CA (1) | CA3168009A1 (https=) |
| IL (1) | IL295149A (https=) |
| MX (1) | MX2022009818A (https=) |
| TW (1) | TW202140026A (https=) |
| WO (1) | WO2021163530A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021163530A1 (en) * | 2020-02-14 | 2021-08-19 | KSQ Therapeutics, Inc. | Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors |
| KR20230098186A (ko) | 2020-10-30 | 2023-07-03 | 케이에스큐 세러퓨틱스 인코포레이티드 | 치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도 |
| US20240409538A1 (en) * | 2021-10-19 | 2024-12-12 | Impact Therapeutics (Shanghai), Inc. | Substituted triazoloheteroaryl compounds as usp1 inhibitors and the use thereof |
| IL312642A (en) * | 2021-11-12 | 2024-07-01 | Insilico Medicine Ip Ltd | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
| EP4430049A4 (en) * | 2021-11-12 | 2025-12-17 | Insilico Medicine Ip Ltd | Small molecule inhibitors of ubiquitin-specific protease 1 (USP1) and uses thereof |
| US20250161306A1 (en) * | 2022-01-25 | 2025-05-22 | KSQ Therapeutics, Inc. | Ubiquitin-specific-processing protease 1 (usp1) inhibitors for the treatment of solid tumors |
| JP2025531133A (ja) * | 2022-09-20 | 2025-09-19 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | ユビキチン特異的プロテアーゼ阻害剤としてのカルボニル縮合複素環誘導体 |
| CA3268518A1 (en) * | 2022-09-23 | 2024-03-28 | KSQ Therapeutics, Inc. | THERAPEUTIC COMBINATIONS INCLUDING UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS (USP1) AND SELECTIVE PARP1 INHIBITORS |
| CN117384187B (zh) * | 2022-09-30 | 2026-01-30 | 轩竹生物科技股份有限公司 | 泛素特异性蛋白酶1抑制剂 |
| EP4605391A1 (en) | 2022-10-21 | 2025-08-27 | Exelixis, Inc. | 4,5,6,7-tetrahydro-1-pyrazolo[4,3-c]pyridine compounds and derivatives as usp1 inhibitors |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| TW202509030A (zh) | 2023-05-08 | 2025-03-01 | 美商譚格醫療公司 | 化合物及使用方法 |
| WO2024233665A1 (en) | 2023-05-08 | 2024-11-14 | Tango Therapeutics, Inc. | Compounds and their use against cancer |
| CN121866064A (zh) * | 2023-06-16 | 2026-04-14 | 韩国科学技术研究院 | 包含BRCA特异性siRNA作为活性成分的用于预防或治疗靶向癌症的药物组合物 |
| WO2025010245A1 (en) | 2023-07-06 | 2025-01-09 | Exelixis, Inc. | Fused pyrazole derivatives as usp1 inhibitors |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025087460A1 (zh) * | 2023-10-25 | 2025-05-01 | 海思科医药集团股份有限公司 | 一种吡啶并吡唑衍生物药物组合物及其应用 |
| WO2025102016A1 (en) | 2023-11-10 | 2025-05-15 | Vrise Therapeutics, Inc. | Novel molecules as inhibitors of dna damage repair pathway |
| TW202539659A (zh) | 2024-01-10 | 2025-10-16 | 美商維瑞斯治療股份有限公司 | Ｄｎａ損傷修復途徑的新穎抑制劑 |
| WO2025153067A1 (zh) * | 2024-01-19 | 2025-07-24 | 江苏亚虹医药科技股份有限公司 | Usp1抑制剂及其医药用途 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025180502A1 (zh) * | 2024-03-01 | 2025-09-04 | 上海齐鲁制药研究中心有限公司 | 一种联合用药物组合物及其用途 |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2797719C (en) * | 2010-04-30 | 2019-11-26 | Dana-Farber Cancer Institute, Inc. | Small molecule inhibitors of usp1 deubiquitinating enzyme activity |
| GB201519573D0 (en) * | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| WO2018165615A1 (en) * | 2017-03-09 | 2018-09-13 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Parp-1 and methods of use thereof |
| KR20190130625A (ko) * | 2017-03-27 | 2019-11-22 | 테사로, 인코포레이티드 | 니라파립 제제 |
| US11485736B2 (en) * | 2018-12-20 | 2022-11-01 | KSQ Therapeutics, Inc. | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors |
| US20230065636A1 (en) * | 2020-01-15 | 2023-03-02 | KSQ Therapeutics, Inc. | Compositions of substituted pyrazolopyrimidines and uses thereof |
| WO2021163530A1 (en) * | 2020-02-14 | 2021-08-19 | KSQ Therapeutics, Inc. | Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors |
| KR20230098186A (ko) * | 2020-10-30 | 2023-07-03 | 케이에스큐 세러퓨틱스 인코포레이티드 | 치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도 |
-
2021
- 2021-02-12 WO PCT/US2021/017912 patent/WO2021163530A1/en not_active Ceased
- 2021-02-12 MX MX2022009818A patent/MX2022009818A/es unknown
- 2021-02-12 US US17/904,159 patent/US20230277533A1/en not_active Abandoned
- 2021-02-12 KR KR1020227027461A patent/KR20220140732A/ko active Pending
- 2021-02-12 CA CA3168009A patent/CA3168009A1/en active Pending
- 2021-02-12 JP JP2022548896A patent/JP2023514568A/ja active Pending
- 2021-02-12 AU AU2021218805A patent/AU2021218805A1/en active Pending
- 2021-02-12 IL IL295149A patent/IL295149A/en unknown
- 2021-02-12 EP EP21754160.6A patent/EP4103165A4/en not_active Withdrawn
- 2021-02-12 CN CN202180013564.7A patent/CN115066235A/zh active Pending
- 2021-02-17 TW TW110105371A patent/TW202140026A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL295149A (en) | 2022-09-01 |
| KR20220140732A (ko) | 2022-10-18 |
| US20230277533A1 (en) | 2023-09-07 |
| MX2022009818A (es) | 2022-09-05 |
| EP4103165A4 (en) | 2024-02-28 |
| TW202140026A (zh) | 2021-11-01 |
| CN115066235A (zh) | 2022-09-16 |
| WO2021163530A1 (en) | 2021-08-19 |
| EP4103165A1 (en) | 2022-12-21 |
| AU2021218805A1 (en) | 2022-09-01 |
| JP2023514568A (ja) | 2023-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3168009A1 (en) | Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors | |
| Secchiero et al. | Recent advances in the therapeutic perspectives of Nutlin-3 | |
| CA3168002C (en) | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | |
| KR20200115607A (ko) | 위장관 기질 종양의 치료를 위한 병용 요법 | |
| KR20240095536A (ko) | 헤테로방향족 매크로사이클릭 에테르 화합물을 사용한 고형 종양의 치료 방법 | |
| US20250177367A1 (en) | Combination therapies for modulation of lipid production | |
| US20190055563A1 (en) | Polymerase q as a target in hr-deficient cancers | |
| US20250213574A1 (en) | Therapeutic combinations comprising ubiquitin- specific-processing protease 1 (usp1) inhibitors and chemotherapy agents | |
| US20230277522A9 (en) | Methods for treating vascular malformations | |
| WO2020056109A1 (en) | Combination cancer therapies | |
| WO2021228814A1 (en) | Mdm2 inhibitor response prediction method | |
| WO2020219926A1 (en) | Treatment of cancer with cdk inhibitors | |
| KR20250091332A (ko) | 유비퀴틴-특이적 처리 프로테아제 1 (usp1) 억제제 및 parp1-선택적 억제제를 포함하는 치료적 조합물 | |
| TWI891650B (zh) | 治療血管畸形之方法 | |
| EA048213B1 (ru) | Терапевтические комбинации, содержащие ингибиторы убиквитин-специфической протеазы 1 (usp1) и ингибиторы поли(адф-рибоза)полимеразы (parp) | |
| CA2673869A1 (en) | Method of treating multidrug resistant cancers | |
| HK40120637A (zh) | 包含泛素特异性加工蛋白酶1(usp1)抑制剂和parp1-选择性抑制剂的治疗组合 | |
| WO2024088193A1 (en) | Combination of aurora a and parp inhibitors for treatment of cancers | |
| Tumbrink | 3.3 MIZ1-∆ POZ shapes treatment response in small cell lung cancer | |
| van Gerven et al. | Screening for differential compound sensitivity in ATRX aberrant models revealed three compounds with general effectivity in neuroblastoma | |
| KR20170119148A (ko) | Myc-ap4 축 활성화된 암의 예방 또는 치료용 조성물의 스크리닝 방법 | |
| CN120456904A (zh) | 用于治疗胶质母细胞瘤的组合治疗 | |
| CN117794548A (zh) | 针对bap1及pbrm1中的至少一个的功能下降的肿瘤的药物组合物及抗肿瘤剂 | |
| WO2021021885A1 (en) | Methods of treating advanced prostate cancer | |
| CN119789871A (zh) | 并用药物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250127 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250127 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250127 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250207 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250207 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250212 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250221 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250224 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250224 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250224 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250506 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260120 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260326 |